Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2432347 | 0.86 | GPR119 (0.51) | GPR119MMP13 | |
| SCHEMBL1576128 | 0.85 | GPR119 (0.73) | GPR119 | |
| SCHEMBL2426771 | 0.85 | GPR119 (0.73) | GPR119 | |
| SCHEMBL1575744 | 0.84 | GPR119 (0.89) | GPR119 | |
| SCHEMBL1574955 | 0.83 | GPR119 (1.00) | GPR119 | |
| SCHEMBL2216375 | 0.80 | GPR119 (0.45) | GPR119MMP13 | |
| SCHEMBL12434644 | 0.80 | GPR119 (0.45) | GPR119MMP13 | |
| SCHEMBL2216383 | 0.80 | GPR119 (0.45) | GPR119MMP13 | |
| SCHEMBL12106817 | 0.80 | GPR119 (0.44) | GPR119 | |
| SCHEMBL26637524 | 0.80 | GPR119 (0.46) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269734-A1 | PIPERIDINYL GPCR AGONISTS | PROSIDION LIMITED (GB) | 2011-11-03 | — | — | US | disclosed |
| US-20110269734-A1 | PIPERIDINYL GPCR AGONISTS | PROSIDION LIMITED (GB) | 2011-11-03 | — | — | US | disclosed |
| US-20110269734-A1 | PIPERIDINYL GPCR AGONISTS | PROSIDION LIMITED (GB) | 2011-11-03 | — | — | US | disclosed |
| EP-2377863-A1 | Piperidine GPCR agonists | Prosidion Limited (GB) | 2011-10-19 | — | — | EP | disclosed |
| US-20110178054-A1 | Heterocyclic GPCR Agonists | PROSIDION LIMITED (GB) | 2011-07-21 | — | — | US | disclosed |
| US-20110178054-A1 | Heterocyclic GPCR Agonists | PROSIDION LIMITED (GB) | 2011-07-21 | — | — | US | disclosed |
| US-20110178054-A1 | Heterocyclic GPCR Agonists | PROSIDION LIMITED (GB) | 2011-07-21 | — | — | US | disclosed |
| US-20100048632-A1 | Piperidine GPCR Agonists | PROSIDION LIMITED (GB) | 2010-02-25 | — | — | US | disclosed |
| US-20100048632-A1 | Piperidine GPCR Agonists | PROSIDION LIMITED (GB) | 2010-02-25 | — | — | US | disclosed |
| WO-2010004343-A1 | PIPERIDINYL GPCR AGONISTS | PROSIDION LIMITED (GB) | 2010-01-14 | — | — | WO | disclosed |
| WO-2010004348-A1 | HETEROCYCLIC GPCR AGONISTS | PROSIDION LIMITED (GB) | 2010-01-14 | — | — | WO | disclosed |
| WO-2008081204-A1 | PIPERIDINE GPCR AGONISTS | PROSIDION LIMITED (GB) | 2008-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048632-A1 | Piperidine GPCR Agonists | GPR119, GPR27, GLP1R | GPR119 1/4885MMP13 3760/4885 |
| US-20110178054-A1 | Heterocyclic GPCR Agonists | GPR119, GCGR, GPR27 | GPR119 1/4885MMP13 4293/4885 |
| US-20110269734-A1 | PIPERIDINYL GPCR AGONISTS | GPR119, GPR27, GLP1R | GPR119 1/4885MMP13 3624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.